Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancy × tremelimumab × Clear all
NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡